| CTRI Number |
CTRI/2022/03/040915 [Registered on: 08/03/2022] Trial Registered Prospectively |
| Last Modified On: |
07/03/2022 |
| Post Graduate Thesis |
No |
| Type of Trial |
Interventional |
|
Type of Study
|
Other (Specify) [Fermented rice water] |
| Study Design |
Randomized, Parallel Group, Placebo Controlled Trial |
|
Public Title of Study
|
Effect of traditional fermented rice-water supplementation to pregnant women |
|
Scientific Title of Study
|
Impact of traditional fermented rice-water on maternal nutrition in Odisha, India |
| Trial Acronym |
|
|
Secondary IDs if Any
|
| Secondary ID |
Identifier |
| NA |
NIL |
|
|
Details of Principal Investigator or overall Trial Coordinator (multi-center study)
|
| Name |
Balamurugan Ramadass |
| Designation |
Additional Professor |
| Affiliation |
All India Institutes for Medical Sciences Bhubaneswar |
| Address |
Room No 149, 1st floor, Department of Biochemistry, Academic Building, AIIMS-BBSR Sijua, Patarapada, Bhubaneswar
Khordha ORISSA 751019 India |
| Phone |
9438884251 |
| Fax |
|
| Email |
balaramadass1@gmail.com |
|
Details of Contact Person Scientific Query
|
| Name |
Balamurugan Ramadass |
| Designation |
Additional Professor |
| Affiliation |
All India Institutes for Medical Sciences Bhubaneswar |
| Address |
Room No 149, 1st floor, Department of Biochemistry, Academic Building, AIIMS-BBSR Sijua, Patarapada, Bhubaneswar
ORISSA 751019 India |
| Phone |
9438884251 |
| Fax |
|
| Email |
balaramadass1@gmail.com |
|
Details of Contact Person Public Query
|
| Name |
Balamurugan Ramadass |
| Designation |
Additional Professor |
| Affiliation |
All India Institutes for Medical Sciences Bhubaneswar |
| Address |
Room No 149, 1st floor, Department of Biochemistry, Academic Building, AIIMS-BBSR Sijua, Patarapada, Bhubaneswar
ORISSA 751019 India |
| Phone |
9438884251 |
| Fax |
|
| Email |
balaramadass1@gmail.com |
|
|
Source of Monetary or Material Support
|
| Bill & Melinda Gates Foundation (BMGF) |
|
|
Primary Sponsor
|
| Name |
Bill Melinda Gates Foundation |
| Address |
Bill & Melinda Gates Foundation
Delhi, India |
| Type of Sponsor |
Other [Global research] |
|
|
Details of Secondary Sponsor
|
|
|
Countries of Recruitment
|
India |
|
Sites of Study
|
| No of Sites = 1 |
| Name of Principal
Investigator |
Name of Site |
Site Address |
Phone/Fax/Email |
| Dr Balamurugan Ramadass |
All India Institute of Medical sciences Bhubaneswar |
Room No. 149, Academic Block, AIIMS-BBSR Khordha ORISSA |
8547805341
balaramadass1@gmail.com |
|
|
Details of Ethics Committee
|
| No of Ethics Committees= 1 |
| Name of Committee |
Approval Status |
| AIIMS Bhubaneswar Ethical committee |
Approved |
|
|
Regulatory Clearance Status from DCGI
|
|
|
Health Condition / Problems Studied
|
| Health Type |
Condition |
| Healthy Human Volunteers |
adult reproductive age women |
|
|
Intervention / Comparator Agent
|
| Type |
Name |
Details |
| Intervention |
Fermented rice water |
500ml per day for 4 months |
| Comparator Agent |
Ready mix rice water |
500ml per day for 4 months |
|
|
Inclusion Criteria
|
| Age From |
18.00 Year(s) |
| Age To |
25.00 Year(s) |
| Gender |
Female |
| Details |
1. Non-pregnant participants: women aged >18 years, staying in the locality and expected to stay for next 6-8 months; access to the phone for contact; not suffering from any major systemic disease, ambulatory
2. Pregnant participants: pregnant women aged >18 years, first trimester pregnancy, no high risk factors or bad obstetric history, staying in the locality and expected to stay for next 6-8 months; access to phone for contact; not suffering from any major systemic disease, ambulatory
|
|
| ExclusionCriteria |
| Details |
1. Refusal for consent, inability to follow the schedule, unwilling to accept or not feasible to consume the fermented rice-water as per schedule |
|
|
Method of Generating Random Sequence
|
Computer generated randomization |
|
Method of Concealment
|
Pre-numbered or coded identical Containers |
|
Blinding/Masking
|
Open Label |
|
Primary Outcome
|
| Outcome |
TimePoints |
| Documentation of the impact of the fermented-rice (Torani) intake on nutrition, gut and vaginal microbiota, gut microbiome, and inflammatory markers in reproductive-age women |
0, 1, 2, 4, and 6 months |
|
|
Secondary Outcome
|
| Outcome |
TimePoints |
| To document effect of the fermented-rice (Torani) intake on inflammatory markers in reproductive-age women |
0, 1, 2, 4, and 6 months |
|
|
Target Sample Size
|
Total Sample Size="200" Sample Size from India="200"
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" |
|
Phase of Trial
|
N/A |
|
Date of First Enrollment (India)
|
14/03/2022 |
| Date of Study Completion (India) |
Applicable only for Completed/Terminated trials |
| Date of First Enrollment (Global) |
Date Missing |
| Date of Study Completion (Global) |
Applicable only for Completed/Terminated trials |
|
Estimated Duration of Trial
|
Years="1" Months="0" Days="0" |
|
Recruitment Status of Trial (Global)
|
Not Yet Recruiting |
| Recruitment Status of Trial (India) |
Not Yet Recruiting |
|
Publication Details
|
NIL |
|
Individual Participant Data (IPD) Sharing Statement
|
Will individual participant data (IPD) be shared publicly (including data dictionaries)?
Response - NO
|
|
Brief Summary
|
We propose to
document the effect of traditional fermented rice-water (Pakhala/Torani) on gut and vaginal microbiome, nutritional profile, and inflammatory markers in reproductive age women in Odisha (India) as an
effort to address the maternal nutritional problem. The Torani is expected to have multidimensional effects including
nutrition (micro-/macro-nutrients), gut microbiome, gut and systemic
inflammation, and source of short-chain fatty acids (SCFAs) for energy. To explore the characterization of the microbiota,
SCFAs, nutrients, and volatile compounds in Torani
samples prepared using different rice types over varying fermentation periods
and the effect on gut microbiota and nutrition and inflammatory markers in
healthy adults for documenting dose effect. |